Morningside Pharmaceuticals Limited Pharmaceutical Import Profile — United Kingdom (DGFT 2022–2026)

Name: Morningside Pharmaceuticals Limited Pharmaceutical Import Records from India — 2 Products, $7.7M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Morningside Pharmaceuticals Limited — Pharmaceutical Importer Profile (2026) | 2 Products, $7.7M Trade | TransData Nexus

Who Are the Verified Indian Suppliers to Morningside Pharmaceuticals Limited?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Usv Private Limited	$16.7M	512	81.1%
Apex Laboratories Private Limited	$1.3M	59	6.3%
Alembic Pharmaceuticals Limited	$1.2M	25	5.8%
Titan Laboratories Private Limited	$475.2K	49	2.3%
Ind Swift Limited	$295.6K	14	1.4%
Macleods Pharmaceuticals Limited	$200.2K	6	1.0%
Encube Ethicals Private Limited	$200.0K	4	1.0%
Vergo Pharma Research Laboratories Private Limited	$146.3K	6	0.7%
Cipla Limited	$71.5K	11	0.3%
Ind-swift Limited	$24.4K	1	0.1%

Morningside Pharmaceuticals Limited sources from 10 verified Indian suppliers across 461 distinct formulations. The sourcing is highly concentrated — Usv Private Limited accounts for 81.1% of total imports, indicating a strategic single-source relationship.

What Formulations Does Morningside Pharmaceuticals Limited Import?

Formulation	Value	Ships
Sukkarto sr 500 MG tabs 14s gb (4x14s)	$353.7K	8
Vensir xl cap 150 MG 28 s (2x14 s) uk	$315.6K	7
Sukkarto sr (metformin hydrochloride	$282.4K	8
Sukkarto sr (metformin hydrochloride)	$260.4K	8
Metformin hcl pr tabs 500 MG 2x14's gb	$254.3K	7
Sukkarto sr (metformin hydrochloride	$250.0K	5
Sukkarto sr (metformin hydrochloride)	$250.0K	5

What Products Does Morningside Pharmaceuticals Limited Import?

Top Products by Import Value

1Metformin$5.6M 2Gabapentin$2.1M

Morningside Pharmaceuticals Limited Therapeutic Categories — 2 Specializations

Morningside Pharmaceuticals Limited imports across 2 therapeutic categories, with Diabetes & Endocrine (72.6%), CNS & Psychiatric (27.4%), representing the largest segments. The portfolio is concentrated — top 5 products = 100% of total imports.

Diabetes & Endocrine

1 products · 72.6% · $5.6M

CNS & Psychiatric

1 products · 27.4% · $2.1M

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Metformin	Diabetes & Endocrine	$5.6M	113	1.2%	13
2	Gabapentin	CNS & Psychiatric	$2.1M	42	0.2%	7

Key Metrics

Total Import Value$7.7M

Products2

Shipments155

Categories2

CountryUnited Kingdom

#1 Rankings0

Indian Suppliers10

Formulations461

Top Categories

Diabetes & Endocrine72.6%

CNS & Psychiatric27.4%

Last updated: March 28, 2026

Morningside Pharmaceuticals Limited — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Morningside Pharmaceuticals Limited, established in 1991, is a UK-based manufacturer, wholesaler, distributor, and exporter of both generic and branded medicines, as well as healthcare products. Headquartered in Loughborough, England, the company has been a significant player in the pharmaceutical sector for over three decades. In October 2022, Morningside was acquired by Aspire Pharma Limited, a move aimed at enhancing their combined growth and international expansion efforts.

The company offers a diverse portfolio covering various therapeutic areas, including cardiology, endocrinology, gynecology, immunology, neurology, oncology, and tuberculosis. Morningside's products are distributed to NHS hospitals and pharmacies across the UK, with global exports reaching over 120 countries. Their clientele includes international aid agencies, charities, and NGOs such as UNICEF, the World Health Organization (WHO), the Red Cross, and Médecins Sans Frontières (MSF).

2Distribution Network

Morningside Pharmaceuticals Limited operates from two primary locations:

Loughborough, England: 5 Pavilion Way, Castle Business Park, Loughborough, LE11 5GW.

Supplier Relationship Intelligence — Morningside Pharmaceuticals Limited

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Morningside Pharmaceuticals Limited's sourcing strategy from India reveals a high concentration on a few suppliers. The company has imported finished pharmaceutical formulations from 10 unique Indian suppliers, with the top five accounting for 96.5% of the total import value. USV Private Limited leads with $16.7 million (81.1% share), followed by Apex Laboratories Private Limited ($1.3 million, 6.3%), Alembic Pharmaceuticals Limited ($1.2 million, 5.8%), Titan Laboratories Private Limited ($475,000, 2.3%), and Ind Swift Limited ($296,000, 1.4%).

This concentration suggests a strategic choice to maintain strong, stable relationships with key suppliers, potentially ensuring consistent product quality and supply reliability. However, such dependency also poses risks, including supply chain disruptions if any of these primary suppliers face operational challenges.

2Supply Chain Resilience

Morningside Pharmaceuticals Limited's supply chain from India appears to be resilient, given the company's reliance on a select group of suppliers. The diversity of formulations imported—461 unique products—indicates a broad product range, which can mitigate risks associated with dependency on specific suppliers. However, the heavy reliance on USV Private Limited (81.1% share) suggests that any disruptions with this supplier could significantly impact Morningside's operations.

To enhance resilience, Morningside could consider diversifying its supplier base further and establishing contingency plans to address potential supply chain disruptions.

3Strategic Implications

Morningside Pharmaceuticals Limited's sourcing pattern, characterized by a high concentration on a few suppliers, positions the company to leverage strong relationships and negotiate favorable terms. This strategy can lead to cost efficiencies and consistent product quality. However, the dependency on a limited number of suppliers also exposes the company to risks such as supply chain disruptions or changes in supplier dynamics.

For Indian exporters, understanding Morningside's sourcing preferences is crucial. Suppliers that can offer a diverse range of formulations and demonstrate reliability may find opportunities to become alternative suppliers to Morningside, potentially reducing the company's supply chain risks.

TransData Nexus Research · Verified DGFT customs dataMar 2026

Importing Pharmaceuticals into United Kingdom — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United Kingdom

1Regulatory Authority & Framework

In the United Kingdom, the Medicines and Healthcare products Regulatory Agency (MHRA) is the primary regulatory body overseeing pharmaceutical imports. The MHRA ensures that medicines and medical devices meet appropriate standards of safety, quality, and efficacy. Key legislation governing pharmaceutical imports includes the Human Medicines Regulations 2012, which transposes EU directives into UK law, and the Medicines Act 1968.

The marketing authorization pathway for Indian generics involves obtaining a UK Marketing Authorization (MA) from the MHRA. This process requires submission of comprehensive data demonstrating the product's quality, safety, and efficacy. Once authorized, the product can be imported and marketed in the UK.

2Import Licensing & GMP

Import licensing requirements in the UK are stringent. Importers must hold a Wholesale Dealer's License issued by the MHRA, which authorizes the importation and distribution of medicinal products. Additionally, Good Manufacturing Practice (GMP) certification is mandatory. The UK recognizes GMP certificates from the European Union (EU GMP), World Health Organization (WHO GMP), and the Pharmaceutical Inspection Co-operation Scheme (PIC/S).

Indian exporters seeking to supply Morningside Pharmaceuticals Limited must ensure their manufacturing facilities are GMP-compliant and hold the necessary certifications recognized by the MHRA.

3Quality & Labeling

Imported pharmaceutical products must undergo batch testing to confirm their quality and compliance with UK standards. Stability requirements ensure that products maintain their efficacy and safety throughout their shelf life. Labeling must be in English and include essential information such as product name, active ingredients, dosage form, strength, batch number, expiry date, storage conditions, and the name and address of the manufacturer. Serialization mandates may apply to facilitate traceability and prevent counterfeit products.

4Recent Regulatory Changes

Between 2024 and 2026, the UK has implemented several regulatory changes affecting pharmaceutical imports. These include updates to the Human Medicines Regulations 2012, adjustments in import licensing procedures, and enhanced requirements for GMP compliance. Additionally, the UK has introduced stricter labeling and serialization requirements to improve product traceability and combat counterfeit medicines.

TransData Nexus Research · United Kingdom regulatory databasesMar 2026

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Buyer Matching: Morningside Pharmaceuticals Limited identified across shipments using consignee name normalization, aggregating 2 name variants.
2.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
3.Market Share: Calculated per product as Morningside Pharmaceuticals Limited's capped value divided by total Indian exports for that product.
4.Shipment Count: Based on 155 individual customs records matching Morningside Pharmaceuticals Limited.
5.Supplier Verification: Morningside Pharmaceuticals Limited sources from 10 verified Indian suppliers across 461 formulations, confirmed from customs records.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

2 Products Tracked

2 therapeutic categories

Expert-Reviewed

By pharmaceutical trade specialists

Morningside Pharmaceuticals Limited

Morningside Pharmaceuticals Limited — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to Morningside Pharmaceuticals Limited?

What Formulations Does Morningside Pharmaceuticals Limited Import?

What Products Does Morningside Pharmaceuticals Limited Import?

Top Products by Import Value

Morningside Pharmaceuticals Limited Therapeutic Categories — 2 Specializations

Import Portfolio — Top 2 by Import Value

Key Metrics

Top Categories

Morningside Pharmaceuticals Limited — Corporate Profile & Information

1Company Overview

2Distribution Network

Indian Suppliers

Related Trade Data

Need Detailed Data?

3Industry Role

Supplier Relationship Intelligence — Morningside Pharmaceuticals Limited

1Sourcing Concentration Analysis

2Supply Chain Resilience

3Strategic Implications

Importing Pharmaceuticals into United Kingdom — Regulatory Framework

1Regulatory Authority & Framework

2Import Licensing & GMP

3Quality & Labeling

4Recent Regulatory Changes

Morningside Pharmaceuticals Limited — Procurement Pattern Analysis

1Product Strategy

2Sourcing Profile

3Market Positioning

Seller's Guide — How to Become a Supplier to Morningside Pharmaceuticals Limited

1Opportunity Assessment

2Requirements & Qualifications

3How to Approach

Frequently Asked Questions — Morningside Pharmaceuticals Limited

What products does Morningside Pharmaceuticals Limited import from India?

Who supplies pharmaceuticals to Morningside Pharmaceuticals Limited from India?

What is Morningside Pharmaceuticals Limited's total pharmaceutical import value?

What therapeutic categories does Morningside Pharmaceuticals Limited focus on?

Get Full Morningside Pharmaceuticals Limited Import Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Data Source & Methodology